Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study)

Torimoto, Kazumasa; Matsushita, Chie; Yamada, Atsushi; Goto, Daisuke; Matsumoto, Yoshihiro; Hosokawa, Yukinari; Miyake, Makito; Aoki, Katsuya; Hirayama, Akihide; Tanaka, Nobumichi; Fujimoto, Kiyohide

doi:10.1002/nau.23050

Cited by 14 publications

(13 citation statements)

References 27 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data were better than the persistence rate with antimuscarinics in previous reports. 11 The differences in tolerability with these two types of medication could greatly influence the continuation of medication. Combination therapy with antimuscarinics and mirabegron could be a better treatment option for female patients' satisfaction.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term persistence with mirabegron in a real‐world clinical setting

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…8 A recent randomized cross-over study also showed that mirabegron had the same efficacy and a lower rate of dry mouth, blurred vision and constipation compared with an antimuscarinic agent imidafenacin. 11 The differences in tolerability with these two types of medication could greatly influence the continuation of medication.…”

Section: Discussionmentioning

confidence: 99%

Long‐term persistence with mirabegron in a real‐world clinical setting

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The efficacy and safety of MIRA has been proved in several phase III clinical trials . Additional studies have shown that MIRA appears to be as effective as antimuscarinics and shows a lower incidence of drug‐related TEAEs . One‐year persistence rates of up to 66.0% have been reported, with improved persistence and adherence versus antimuscarinic therapy …”

Section: Introductionmentioning

confidence: 99%

“…6,7 Additional studies have shown that MIRA appears to be as effective as antimuscarinics and shows a lower incidence of drug-related TEAEs. 8,9 One-year persistence rates of up to 66.0% have been reported, with improved persistence and adherence versus antimuscarinic therapy. 10,11 International urological associations recommend MIRA and antimuscarinics for treating patients with OAB symptoms.…”

mentioning

confidence: 99%

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)

Yamaguchi

Κakizaki²,

Homma

et al. 2018

Int J of Urology

View full text Add to dashboard Cite

Objectives To evaluate the long‐term safety (primary objective) and efficacy (secondary objective) of antimuscarinic add‐on therapy in patients receiving mirabegron. Methods During a 2‐week screening period, patients (aged ≥20 years, mirabegron treatment for ≥6 weeks, residual overactive bladder symptoms) received mirabegron 50 mg once daily. These patients were subsequently randomized to 52 weeks’ treatment with mirabegron 50 mg/day plus an antimuscarinic (solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2 mg, or tolterodine 4 mg) with the potential to double the antimuscarinic dose (except for tolterodine) at week 8. Safety assessments included treatment‐emergent adverse events, vital signs, 12‐lead electrocardiograms, post‐void residual volume, and laboratory evaluations. Efficacy was assessed using changes from baseline in overactive bladder symptom score total score; overactive bladder questionnaire short form score; micturitions, urgency episodes, urinary incontinence episodes, and urgency urinary incontinence episodes/24 h; mean volume voided per micturition; and number of night‐time micturitions. Results Overall, 80.2% of patients (88.1% women, mean age 65 years) experienced at least one treatment‐emergent adverse event, with similar rates for all treatments. The adverse events most commonly reported were dry mouth, nasopharyngitis, and constipation. No marked change was observed in systolic or diastolic blood pressure for any treatment, although pulse rate increased slightly in the mirabegron and propiverine, and mirabegron and tolterodine groups. For all treatments, significant improvements were observed in all efficacy parameters, including overactive bladder symptom score total and questionnaire short form scores. Conclusions Antimuscarinic add‐on therapy is well tolerated and effective after initial treatment with mirabegron in patients with overactive bladder symptoms.

show abstract

“…There is accumulating evidence that mirabegron has about the same degree of effectiveness as a standard antimuscarinic [30,31] and that combination therapy with an antimuscarinic can produce improved control of symptoms [32]. Concerns about cardiovascular toxicity have largely proven to be unfounded [33].…”

Section: Second Line: Pharmacologicalmentioning

confidence: 99%

Urinary Urgency in the Elderly

Potts¹,

Payne²

2018

Gerontology

View full text Add to dashboard Cite

The last 2 decades have brought an explosion of research, new products, and general attention to the problem of urinary urgency, and yet patients continue to be plagued by this symptom – especially the elderly. What is it? What does it mean? How can we guide patients successfully through this challenge? This paper presents a review of current thinking about urgency relevant to the practicing clinician, including the epidemiology, pathophysiology, evaluation, and treatment of these patients.

show abstract

Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study)

Abstract: Mirabegron and imidafenacin have the same efficacy. Imidafenacin administration is associated with a higher rate of dry mouth, blurred vision, and constipation as compared to mirabegron administration. Neurourol. Urodynam. 36:1097-1103, 2017. © 2016 Wiley Periodicals, Inc.

Cited by 14 publications

References 27 publications

Long‐term persistence with mirabegron in a real‐world clinical setting

Long‐term persistence with mirabegron in a real‐world clinical setting

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)

Urinary Urgency in the Elderly

Contact Info

Product

Resources

About